SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Undisclosed

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Ocular Therapeutix

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 29, 2021

            Details:

            Under terms of the agreement, the collaboration between Ocular Therapeutix and Mosaic focuses on the discovery and development of novel complement inhibitors with extended duration of activity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Undisclosed

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: National Eye Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding October 29, 2020

            Details:

            Synedgen has developed a new class of glycopolymers with the ability to suppress inflammation, reduce infection, and improve healing at mucosal surfaces. The additional funding provides resources to optimize down-selection to a lead molecule to advance into animal studies.